Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Future Oncol
; 12(22): 2561-2578, 2016 Nov.
Article
en En
| MEDLINE
| ID: mdl-27412069
ABSTRACT
Neuroendocrine tumors (NETs) are a rare diverse group of malignancies occurring most commonly in the gastroenteropancreatic system and the lungs. The incidence of NETs is increasing worldwide; median survival for patients with metastatic NETs is 5-65 months. A growing body of evidence shows survival benefit in patients with advanced NETs (gastroenteropancreatic and lung) treated with mTOR inhibitor everolimus, with improvement in survival being demonstrated in the clinical trial and real-world setting. Everolimus has been shown to have a manageable safety profile, with the most common adverse events being stomatitis, rash, diarrhea, fatigue and infections. Due to the rarity of the condition, there are challenges in conducting clinical trials in these patients. Further research is required to clarify the role of adjuvant therapy, treatment sequencing and the use of multimodality treatments.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Neoplasias Gástricas
/
Tumores Neuroendocrinos
/
Inhibidores de Proteínas Quinasas
/
Everolimus
/
Neoplasias Intestinales
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2016
Tipo del documento:
Article
País de afiliación:
Reino Unido